The ULTIMATE-DAPT study found that withdrawing aspirin one month after PCI in high-risk heart patients and keeping them on ticagrelor alone significantly reduces major bleeding by more than 50% compared to patients on aspirin and ticagrelor. This change in treatment did not increase adverse ischemic events. The study involved 3,400 ACS patients and was conducted across multiple centers. The results suggest that discontinuing aspirin after PCI in stable patients can improve outcomes without increasing the risk of heart attack or other complications. This approach may lead to changes in clinical guidelines for ACS patients worldwide.
Source link
Stopping aspirin 1 month after coronary stenting significantly reduces bleeding complications in heart attack patients
